Brain Disorders & Therapy

Hagerman R, Ligsay A, Goldberg J. Aging with Neurodevelopmental Disorders: On-Call Assessment and Future Directions. InOn-Call Geriatric Psychiatry 2016 (pp. 341-351). Springer International Publishing.

Hagerman RJ, Wheeler A, Fitzpatrick S, Hunter J. Premutation-Associated Disorders in Childhood and Adulthood. InFXTAS, FXPOI, and Other Premutation Disorders 2016: 241-262.

Hagerman R, Ligsay A, Goldberg J. Aging with Neurodevelopmental Disorders: On-Call Assessment and Future Directions. InOn-Call Geriatric Psychiatry.  2016:341-351. 

Gossett A, Sansone S, Schneider A, Johnston C, Hagerman R, Tassone F, Rivera SM, Seritan AL, Hessl D. Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2016 Dec 1;171(8):1139-47.

Famula J, Basuta K, Gane LW, Hagerman RJ, Tassone F. Identification of a male with fragile X syndrome through newborn screening. Intractable & rare diseases research. 2015;4(4):198-202.

Wang JY, Hessl D, Hagerman RJ, Simon TJ, Tassone F, Ferrer E, Rivera SM. Abnormal Trajectories in Cerebellum and Brainstem Volumes in Carriers of the Fragile X Premutation. Neurobiology of Aging. 2017 Mar 18.

Milà M, Rodriguez-Revenga L, Matilla-Dueñas A. FMR1 Premutation: Basic Mechanisms and Clinical Involvement.

Botta-Orfila T, Tartaglia GG, Michalon A. Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development. The Cerebellum. 2016 Oct 1;15(5):599-610.

Hagerman R. Psychopathology Increases With Age in Fragile X Carrier Mothers. Biological psychiatry. 2016 May 15;79(10):790-1.

Rajan-Babu IS, Chong SS. Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders. Genes. 2016 Oct 14;7(10):87.

Hagerman RJ, Hagerman PJ. Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. Genetic Disorders and the Fetus: Diagnosis, Prevention, and Treatment. 2015 Sep 16:350.

Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome [mdash] features, mechanisms and management. Nature Reviews Neurology. 2016 Jul 1;12(7):403-12.

Lozano R, Martinez-Cerdeno V, J Hagerman R. Advances in the understanding of the gabaergic neurobiology of FMR1 expanded alleles leading to targeted treatments for Fragile X Spectrum disorder. Current pharmaceutical design. 2015 Oct 1;21(34):4972-9.

Muzar Z, Lozano R. Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome. Intractable & rare diseases research. 2014 Nov 30;3(4):101-9.

Saldarriaga W, Lein P, Teshima LY, Isaza C, Rosa L, Polyak A, Hagerman R, Girirajan S, Silva M, Tassone F. Phenobarbital use and neurological problems in FMR1 premutation carriers. Neurotoxicology. 2016 Mar 31;53:141-7.

Cordeiro L, Abucayan F, Hagerman R, Tassone F, Hessl D. Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable & rare diseases research. 2015;4(3):123-30.

Hagerman PJ, Hagerman RJ. Fragile X–associated tremor/ataxia syndrome. Annals of the New York Academy of Sciences. 2015 Mar 1;1338(1):58-70.

Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’system?. Acta neuropathologica. 2018;135:387-407.

Shukla P, Tyagi N. Research and Reviews: Journal of Medical and Health Sciences.

Spector R, Snodgrass SR, Johanson CE. A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans. Experimental neurology. 2015;273:57-68.